ETC 276

Drug Profile

ETC 276

Alternative Names: ProApo A-1; Proapolipoprotein A-1

Latest Information Update: 10 Dec 2007

Price : $50

At a glance

  • Originator Esperion Therapeutics
  • Class Antihyperlipidaemics
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 31 Dec 2002 Suspended - Phase-I for Atherosclerosis in USA (IV)
  • 24 Nov 2000 Phase-I clinical trials for Atherosclerosis in USA (IV)
  • 24 Feb 2000 Preclinical development for Atherosclerosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top